APOA5 and metabolic syndrome: Although a previous study has reported the effect of APOA5 on CD4 levels, individuals with the minor allelic variant of APOA5 (rs662799) A>G have a significant likelihood of developing dyslipidemia in HIV subjects on ART after controlling for CD4 counts as well as age, gender, duration of treatment and BMI.